$ATIP
ATI Physical Therapy, Inc. Stock $atip

$atip Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000181584923000007 Filed on May 08, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$172.3M	$166.9M	$153.8M
YoY Change	5.54%	8.52%	3.19%
Cost Of Revenue	$145.8M	$143.6M	$139.0M
YoY Change	4.11%	3.27%	12.17%
Gross Profit	$26.57M	$23.35M	$14.79M
YoY Change	14.14%	57.86%	-41.1%
Gross Profit Margin	15.42%	13.99%	9.62%
Selling, General & Admin	$36.57M	$30.60M	$30.02M
YoY Change	14.06%	1.9%	21.43%
% of Gross Profit	137.63%	131.02%	202.97%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$9.165M	$9.691M	$10.11M
YoY Change	-10.66%	-4.15%	5.11%
% of Gross Profit	34.49%	41.5%	68.35%
Operating Expenses	$36.57M	$30.60M	$30.02M
YoY Change	3.57%	1.9%	21.43%
Operating Profit	-$12.36M	-$11.37M	-$176.1M
YoY Change	2.73%	-93.54%	2495.11%
Interest Expense	-$16.68M	-$13.94M	-$8.656M
YoY Change	46.6%	61.0%	-59.54%
% of Operating Profit
Other Income/Expense, Net	-$618.0K	-$354.0K	-$2.781M
YoY Change	-124.97%	-87.27%	1717.65%
Pretax Income	-$21.66M	-$25.15M	-$161.5M
YoY Change	-85.44%	-84.43%	470.02%
Income Tax	$100.0K	$100.0K	-$23.30M
% Of Pretax Income
Net Earnings	-$22.71M	-$26.27M	-$137.8M
YoY Change	-83.25%	-80.93%	620.19%
Net Earnings / Revenue	-13.17%	-15.74%	-89.55%
Basic Earnings Per Share	-$17.74	-$0.15	-$0.70
Diluted Earnings Per Share	-$17.74	-$0.15	-$0.70
COMMON SHARES
Basic Shares Outstanding	208.5M shares	207.4M shares	200.0M shares
Diluted Shares Outstanding	4.122M shares	204.9M shares	200.0M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$37.70M	$63.08M	$94.80M
YoY Change	-52.69%	-33.46%	58225.85%
Cash & Equivalents	$37.68M	$63.08M	$94.80M
Short-Term Investments
Other Short-Term Assets	$6.225M	$6.722M	$6.658M
YoY Change	-77.51%	0.96%	1815.2%
Inventory
Prepaid Expenses	$14.30M	$9.373M	$8.706M
Receivables	$80.78M	$82.21M	$87.81M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$139.0M	$166.8M	$198.0M
YoY Change	-27.06%	-15.72%	38704.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$114.8M	$119.5M	$136.8M
YoY Change	-69.85%	-12.63%
Goodwill	$289.7M	$286.5M	$492.2M
YoY Change		-41.81%	-62.14%
Intangibles	$246.2M	$246.4M	$372.1M
YoY Change		-33.78%
Long-Term Investments
YoY Change
Other Assets	$1.862M	$1.823M	$2.811M
YoY Change	-7.5%	-35.15%
Total Long-Term Assets	$871.3M	$878.9M	$1.259B
YoY Change	-22.14%	-30.21%	265.0%
TOTAL ASSETS
Total Short-Term Assets	$139.0M	$166.8M	$198.0M
Total Long-Term Assets	$871.3M	$878.9M	$1.259B
Total Assets	$1.010B	$1.046B	$1.457B
YoY Change	-22.86%	-28.24%	321.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.54M	$10.25M	$12.26M
YoY Change	-12.76%	-16.46%	122.67%
Accrued Expenses	$109.1M	$94.50M	$102.6M
YoY Change	-0.77%	-7.93%	208022.47%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$126.5M	$111.2M	$122.3M
YoY Change	-4.1%	-9.06%	2100.9%
LONG-TERM LIABILITIES
Long-Term Debt	$512.0M	$534.1M	$477.8M
YoY Change	7.0%	11.79%
Other Long-Term Liabilities	$1.644M	$1.821M	$2.348M
YoY Change	-99.37%	-22.44%	-92.86%
Total Long-Term Liabilities	$1.644M	$536.0M	$480.2M
YoY Change	-99.78%	11.62%	1360.65%
TOTAL LIABILITIES
Total Short-Term Liabilities	$126.5M	$111.2M	$122.3M
Total Long-Term Liabilities	$1.644M	$536.0M	$480.2M
Total Liabilities	$869.6M	$884.9M	$918.7M
YoY Change	-4.24%	-3.67%	2290.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.388B	-$1.366B	-$984.9M
YoY Change		38.67%	16854.9%
Common Stock	$0.00	$20.00K	$20.00K
YoY Change		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$100.0K
YoY Change
Treasury Stock Shares			40.00K shares
Shareholders Equity	-$78.08M	$15.64M	$392.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.010B	$1.046B	$1.457B
YoY Change	-22.86%	-28.24%	321.76%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$22.71M	-$26.27M	-$137.8M
YoY Change	-83.25%	-80.93%	620.19%
Depreciation, Depletion And Amortization	$9.165M	$9.691M	$10.11M
YoY Change	-10.66%	-4.15%	5.11%
Cash From Operating Activities	$8.905M	-$14.20M	-$26.73M
YoY Change	-248.27%	-46.88%	-11.11%
INVESTING ACTIVITIES
Capital Expenditures	$4.556M	$5.434M	$8.772M
YoY Change	-150.24%	-38.05%	4.73%
Acquisitions
YoY Change
Other Investing Activities	-$490.0K	$355.0K	$114.0K
YoY Change	-549.54%	211.4%	308.6%
Cash From Investing Activities	-$5.046M	-$5.079M	-$8.658M
YoY Change	-43.68%	-41.34%	-1.19%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net		$0.00	$555.0M
YoY Change		-100.0%	27081.59%
Cash From Financing Activities	-29.26M	-$761.0K	$81.57M
YoY Change	19274.17%	-100.93%	-1552.2%
NET CHANGE
Cash From Operating Activities	8.905M	-$14.20M	-$26.73M
Cash From Investing Activities	-5.046M	-$5.079M	-$8.658M
Cash From Financing Activities	-29.26M	-$761.0K	$81.57M
Net Change In Cash	-25.40M	-$20.06M	$46.18M
YoY Change	68.0%	-143.45%	-203.89%
FREE CASH FLOW
Cash From Operating Activities	$8.905M	-$14.20M	-$26.73M
Capital Expenditures	$4.556M	$5.434M	$8.772M
Free Cash Flow	$4.349M	-$19.63M	-$35.50M
YoY Change	41.98%	-44.7%	-7.66%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001815849
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-39439
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ATI Physical Therapy, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1408039
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	790 Remington Boulevard
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Bolingbrook
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	IL
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	60440
CY2023Q1	dei	City Area Code CityAreaCode	630
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	296-2223
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	208495548	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	63075000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83139000	usd
CY2023Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	52549000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	47620000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	82210000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	80673000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9373000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	13526000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	6722000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	10040000	usd
CY2023Q1	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	5469000	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	6755000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	166849000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	194133000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	119508000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123690000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	224725000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	226092000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	286458000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286458000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246398000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246582000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1823000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2030000	usd
CY2023Q1	us-gaap	Assets Assets	1045761000	usd
CY2022Q4	us-gaap	Assets Assets	1078985000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10245000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12559000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	47564000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	53672000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	51911000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47676000	usd
CY2023Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1503000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	2614000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	111223000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	116521000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	534137000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	531600000	usd
CY2023Q1	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	296000	usd
CY2022Q4	ati	Warrant Liability Noncurrent WarrantLiabilityNoncurrent	98000	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2126000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	2835000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	18948000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	18886000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216396000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	218424000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1821000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1834000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	884947000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	890198000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2023Q1	ati	Temporary Equity Par Value Per Share TemporaryEquityParValuePerShare	0.0001
CY2022Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2023Q1	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1140.48
CY2022Q4	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1108.34
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140340000	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	140340000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	470000000	shares
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11400000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	208700000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	199500000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	207500000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	198400000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	20000	usd
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	240000	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	80000.00	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	197000	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	146000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1380150000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1378696000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1443000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	4899000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1365781000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1339511000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15635000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	43958000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	4839000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	4489000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20474000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48447000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1045761000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1078985000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	166932000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153822000	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	90703000	usd
CY2022Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	87415000	usd
CY2023Q1	ati	Rent Clinic Supplies Contract Labor And Other Operating Expenses RentClinicSuppliesContractLaborAndOtherOperatingExpenses	52878000	usd
CY2022Q1	ati	Rent Clinic Supplies Contract Labor And Other Operating Expenses RentClinicSuppliesContractLaborAndOtherOperatingExpenses	51615000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4125000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5105000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	147706000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	144135000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30595000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30024000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	155741000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11369000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-176078000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	198000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1677000	usd
CY2023Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	709000	usd
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	24334000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-13936000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-8656000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-354000	usd
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2781000	usd
CY2023Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-25148000	usd
CY2022Q1	us-gaap	Income Loss Including Portion Attributable To Noncontrolling Interest IncomeLossIncludingPortionAttributableToNoncontrollingInterest	-161504000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	62000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23281000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-25210000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1060000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26270000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-137750000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204921000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204921000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	199971000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199971000	shares
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-25210000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-3456000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	3752000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-28666000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-134471000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	1060000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-473000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29726000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-133998000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	48447000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	51000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1454000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-3456000	usd
CY2023Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	710000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1060000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-26270000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20474000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	511507000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	22000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1960000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	3752000	usd
CY2022Q1	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	473000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-137750000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	398226000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-25210000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	usd
CY2023Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	155741000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9691000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10111000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4125000	usd
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	5105000	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	62000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-23281000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11850000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11807000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1454000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1960000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	838000	usd
CY2022Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	660000	usd
CY2023Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1736000	usd
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	0	usd
CY2023Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022Q1	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2809000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	-489000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	219000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	198000	usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1677000	usd
CY2023Q1	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-709000	usd
CY2022Q1	ati	Change In Fair Value Of Contingent Common Share Liability ChangeInFairValueOfContingentCommonShareLiability	-24334000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5770000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10459000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-4073000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-588000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-33000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-14000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-2439000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-928000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-6168000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-544000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-8476000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-11555000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-37000	usd
CY2023Q1	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	0	usd
CY2022Q1	ati	Increase Decrease In Medicare Accelerated And Advance Payment Funds IncreaseDecreaseInMedicareAcceleratedAndAdvancePaymentFunds	-4269000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14224000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26731000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5434000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8772000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	114000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-5079000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-8658000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	500000000	usd
CY2023Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	12952000	usd
CY2023Q1	ati	Payment Of Debt Issuance Discount PaymentOfDebtIssuanceDiscount	0	usd
CY2022Q1	ati	Payment Of Debt Issuance Discount PaymentOfDebtIssuanceDiscount	10000000	usd
CY2023Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	555048000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	144667000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	usd
CY2023Q1	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	0	usd
CY2022Q1	ati	Payment Of Stock Issuance Costs And Issuance Discounts PaymentOfStockIssuanceCostsAndIssuanceDiscounts	4935000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	51000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	22000	usd
CY2023Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	710000	usd
CY2022Q1	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	473000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-761000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	81570000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20064000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	46181000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83139000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48616000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	63075000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	94797000	usd
CY2023Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	-3456000	usd
CY2022Q1	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	3752000	usd
CY2023Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1771000	usd
CY2022Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	2223000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	9563000	usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3932000	usd
CY2023Q1	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	3418000	usd
CY2022Q1	us-gaap	Derivative Cash Received On Hedge DerivativeCashReceivedOnHedge	0	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	35000	usd
CY2023Q1	us-gaap	Nature Of Operations NatureOfOperations	Overview of the Company<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATI Physical Therapy, Inc., together with its subsidiaries (herein referred to as “we,” “the Company,” “ATI Physical Therapy” and “ATI”), is a nationally recognized healthcare company, specializing in outpatient rehabilitation and adjacent healthcare services. The Company provides outpatient physical therapy services under the name ATI Physical Therapy and, as of March 31, 2023, had 909 clinics located in 24 states (as well as 19 clinics under management service agreements). The Company offers a variety of services within its clinics, including physical therapy to treat spine, shoulder, knee and neck injuries or pain; work injury rehabilitation services, including work conditioning and work hardening; hand therapy; and other specialized treatment services. The Company’s direct and indirect wholly-owned subsidiaries include, but are not limited to, Wilco Holdco, Inc., ATI Holdings Acquisition, Inc. and ATI Holdings, LLC.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19 and CARES Act</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The coronavirus ("COVID-19") pandemic in the United States resulted in changes to our operating environment. We continue to closely monitor the impact of COVID-19 on all aspects of our business, and our priorities remain protecting the health and safety of employees and patients, maximizing the availability of services to satisfy patient needs and improving the operational and financial stability of our business. While we expect the disruption caused by COVID-19 and resulting impacts to diminish over time, we cannot predict the length of such impacts, and if such impacts continue for an extended period, it could have a continued effect on the Company’s results of operations, financial condition and cash flows, which could be material.</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was signed into law providing reimbursement, grants, waivers and other funds to assist health care providers during the COVID-19 pandemic. The Company realized benefits under the CARES Act including, but not limited to, the receipt of Medicare Accelerated and Advance Payment Program ("MAAPP") funds and deferral of depositing the employer portion of Social Security taxes, interest-free and penalty-free. During the year ended December 31, 2022, the remaining obligations related to these benefits were applied and repaid. During the three months ended March 31, 2022, the Company applied $4.3 million in MAAPP funds against the outstanding liability at that time.</span></div>
CY2023Q1	us-gaap	Number Of Stores NumberOfStores	909	clinic
CY2023Q1	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	24	state
CY2023Q1	ati	Number Of Stores Under Management Service Agreements NumberOfStoresUnderManagementServiceAgreements	19	clinic
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14200000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-25200000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the condensed consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. The effect of any change in estimates will be recognized in the current period of the change.</span></div>
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2023Q1	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	800000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	166932000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	153822000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	286458000	usd
CY2023Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023Q1	us-gaap	Goodwill Goodwill	286458000	usd
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	1045700000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246398000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	246582000	usd
CY2022Q1	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	116300000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	355660000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	352896000	usd
CY2023Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	236152000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	229206000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	119508000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123690000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	9507000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	9921000	usd
CY2023Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	16786000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	28949000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7948000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	5551000	usd
CY2023Q1	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	6734000	usd
CY2022Q4	us-gaap	Health Care Organization Accounts Payable To Third Party Payor HealthCareOrganizationAccountsPayableToThirdPartyPayor	6117000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	6089000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	762000	usd
CY2023Q1	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	2685000	usd
CY2022Q4	ati	Accrued Contract Labor Current AccruedContractLaborCurrent	4483000	usd
CY2023Q1	ati	Accrued Occupancy Costs Current AccruedOccupancyCostsCurrent	2350000	usd
CY2022Q4	ati	Accrued Occupancy Costs Current AccruedOccupancyCostsCurrent	2410000	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4972000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5400000	usd
CY2023Q1	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	47564000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	53672000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	10693000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	11137000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8587000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	8944000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	534137000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	531600000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	534137000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	531600000	usd
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	0	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	48200000	usd
CY2023Q1	ati	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	505217000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	553417000	usd
CY2023Q1	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	19280000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	534137000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1500000	usd
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	200000	shares
CY2023Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	200000	shares
CY2022Q1	ati	Proceeds From Issuance Of Temporary Equity And Warrants ProceedsFromIssuanceOfTemporaryEquityAndWarrants	165000000	usd
CY2023Q1	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1140.48
CY2022Q4	ati	Temporary Equity Stated Value Per Share TemporaryEquityStatedValuePerShare	1108.34
CY2022Q1	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	20333000	usd
CY2022Q1	ati	Class Of Warrant Or Right Unamortized Discount ClassOfWarrantOrRightUnamortizedDiscount	203000	usd
CY2022Q1	ati	Class Of Warrant Or Right Issuance Cost ClassOfWarrantOrRightIssuanceCost	405000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	19725000	usd
CY2023Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	101634000	shares
CY2023Q1	us-gaap	Shares Paid For Tax Withholding For Share Based Compensation SharesPaidForTaxWithholdingForShareBasedCompensation	160000	shares
CY2023Q1	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	240000	shares
CY2023Q1	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	200000	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	11.50
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	-99000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	-3357000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax	3681000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Reclassification After Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax	71000	usd
CY2023Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.144
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23300000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	100000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23300000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16689000	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	16703000	usd
CY2023Q1	us-gaap	Variable Lease Cost VariableLeaseCost	5362000	usd
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	5205000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	22051000	usd
CY2022Q1	us-gaap	Lease Cost LeaseCost	21908000	usd
CY2023Q1	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	5900000	usd
CY2023Q1	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	5900000	usd
CY2022Q1	ati	Lease Modification Operation Lease Liabilities Additions LeaseModificationOperationLeaseLiabilitiesAdditions	5700000	usd
CY2022Q1	ati	Lease Modification Operating Lease Assets Additions LeaseModificationOperatingLeaseAssetsAdditions	5700000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	13133000	usd
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	16438000	usd
CY2023Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4898000	usd
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5142000	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y9M18D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	7.1
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	6.9
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	51578000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	64446000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	54923000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	48378000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	37201000	usd
CY2023Q1	ati	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	73641000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	330167000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	61860000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	268307000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	51911000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	216396000	usd
CY2023Q1	us-gaap	Contractual Obligation ContractualObligation	15200000	usd
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	450000000	shares
CY2022Q4	ati	Loss Contingency Number Of Plaintiffs Who Filed Consolidated Amended Complaint LossContingencyNumberOfPlaintiffsWhoFiledConsolidatedAmendedComplaint	4	segment
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-25210000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-138223000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	1060000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-473000	usd
CY2023Q1	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	5303000	usd
CY2022Q1	ati	Temporary Equity Cumulative Dividend TemporaryEquityCumulativeDividend	1925000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-31573000	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-31573000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-139675000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-139675000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	204921000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	204921000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	199971000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	199971000	shares
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.15
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.70
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.70
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	59696000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27544000	shares

Files In Submission

Name	View Source	Status
ati-20230331_lab.xml	Edgar Link	unprocessable
0001815849-23-000007-index-headers.html	Edgar Link	pending
0001815849-23-000007-index.html	Edgar Link	pending
0001815849-23-000007.txt	Edgar Link	pending
0001815849-23-000007-xbrl.zip	Edgar Link	pending
ati-20230331.htm	Edgar Link	pending
ati-20230331.xsd	Edgar Link	pending
ati-20230331_cal.xml	Edgar Link	unprocessable
ati-20230331_def.xml	Edgar Link	unprocessable
ati-20230331_g1.jpg	Edgar Link	pending
ati-20230331_g2.jpg	Edgar Link	pending
exhibit311_q12023.htm	Edgar Link	pending
exhibit312_q12023.htm	Edgar Link	pending
exhibit32_q12023.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
ati-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
ati-20230331_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ATIP
ATI Physical Therapy, Inc. Stock $atip

2023 Q2 Form 10-Q Financial Statement

#000181584923000007 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP ATI Physical Therapy, Inc. Stock $atip

2023 Q2 Form 10-Q Financial Statement

#000181584923000007 Filed on May 08, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ATIP
ATI Physical Therapy, Inc. Stock $atip